Nicholas J. Vogelzang, MD, head of the Genitourinary Cancer Program at the Comprehensive Cancer Centers of Nevada discusses the 6 mortalities in the cabozantinib (XL184) phase II randomized discontinuation trial for patients with advanced solid tumors.

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


ASCO Annual Meeting

Dr. Vogelzang from the Comprehensive Cancer Centers of Nevada discusses mortalities in cabozantinib trial.

Dr. Vogelzang on Mortalities in the Cabozantinib Trial